Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 25.8%

Arcellx, Inc. (NASDAQ:ACLX) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 8,112,318 shares, a growth of 25.8% from the November 30th total of 6,449,275 shares. Based on an average trading volume of 1,529,016 shares, the short-interest ratio is presently 5.3 days. Currently, 15.3% of the shares of the company are sold short. Currently, 15.3% of the shares of the company are sold short. Based on an average trading volume of 1,529,016 shares, the short-interest ratio is presently 5.3 days.

Insider Transactions at Arcellx

In other Arcellx news, insider Christopher Heery sold 340 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $90.00, for a total value of $30,600.00. Following the completion of the transaction, the insider owned 284 shares of the company’s stock, valued at $25,560. This represents a 54.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 8.35% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcellx

Large investors have recently bought and sold shares of the business. Teacher Retirement System of Texas increased its holdings in Arcellx by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 8,883 shares of the company’s stock valued at $585,000 after purchasing an additional 151 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Arcellx by 7.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 3,428 shares of the company’s stock worth $226,000 after purchasing an additional 228 shares during the last quarter. CWM LLC increased its stake in shares of Arcellx by 267.0% in the third quarter. CWM LLC now owns 345 shares of the company’s stock valued at $28,000 after buying an additional 251 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in shares of Arcellx by 9.0% in the third quarter. Integrated Wealth Concepts LLC now owns 3,423 shares of the company’s stock valued at $281,000 after buying an additional 283 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Arcellx by 15.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,129 shares of the company’s stock valued at $140,000 after buying an additional 290 shares during the last quarter. 96.03% of the stock is currently owned by institutional investors.

Arcellx Price Performance

Arcellx stock opened at $63.60 on Wednesday. The firm has a market capitalization of $3.68 billion, a P/E ratio of -16.18 and a beta of 0.34. The stock has a fifty day moving average price of $77.65 and a two-hundred day moving average price of $74.84. Arcellx has a 52-week low of $47.86 and a 52-week high of $94.07.

Arcellx (NASDAQ:ACLX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.03). The firm had revenue of $4.95 million during the quarter, compared to the consensus estimate of $11.24 million. Arcellx had a negative return on equity of 51.13% and a negative net margin of 607.01%. On average, equities research analysts predict that Arcellx will post -1.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ACLX. Needham & Company LLC restated a “buy” rating and set a $105.00 price objective on shares of Arcellx in a research report on Monday, December 8th. Stifel Nicolaus set a $129.00 price target on shares of Arcellx and gave the stock a “buy” rating in a research note on Thursday, October 16th. Citigroup restated a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Wells Fargo & Company began coverage on shares of Arcellx in a report on Monday, December 22nd. They set an “overweight” rating and a $100.00 price objective for the company. Finally, Guggenheim reissued a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Arcellx presently has a consensus rating of “Moderate Buy” and an average target price of $113.75.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.